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AutophagyPancreatic cancer ranks fourth among cancer-related causes of death in North America. Minimal progress has been
made in the diagnosis and treatment of patientswith late-stage tumors.Moreover, pancreatic cancer aggressiveness
is closely related to high levels of pro-survival mediators, which can ultimately lead to rapid disease progression, re-
sistance and metastasis. The main goal of this study was to deﬁne the mechanisms by which calix[6]arene, but not
other calixarenes, efﬁciently decreases the aggressiveness of a drug resistant human pancreas carcinoma cell line
(Panc-1). Calix[6]arenewasmore potent in reducing Panc-1 cell viability than gemcitabine and 5-ﬂuorouracil. In re-
lation to the underlying mechanisms of cytotoxic effects, it led to cell cycle arrest in the G0/G1 phase through
downregulation of PIM1, CDK2, CDK4 and retinoblastoma proteins. Importantly, calix[6]arene abolished signal
transduction of Mer and AXL tyrosine kinase receptors, both of which are usually overexpressed in pancreatic
cancer. Accordingly, inhibition of PI3K and mTOR was also observed, and these proteins are positively modulated
by Mer and AXL. Despite decreasing the phosphorylation of AKT at Thr308, calix[6]arene caused an increase in
phosphorylation at Ser473. These ﬁndings in conjunction with increased BiP and IRE1-α provide a molecular
basis explaining the capacity of calix[6]arene to trigger endoplasmic reticulum stress and autophagic cell death.
Our ﬁndings highlight calix[6]arene as a potential candidate for overcoming pancreatic cancer aggressiveness.
Importantly, we provide evidence that calix[6]arene affects a broad array of key targets that are usually dysfunc-
tional in pancreatic cancer, a highly desirable characteristic for chemotherapeutics.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Pancreatic cancer is the fourth leading cause of cancer-related deaths
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ights reserved.disease stages [2]. In addition, the high heterogeneity of pancreatic
cancer, caused by the deregulation of multiple signaling pathways,
culminates in the inherent or acquired resistance to chemotherapy,
radiotherapy, or both [3,4]. Due to this, current therapeutic approaches
for treating pancreatic cancer are rather inefﬁcient and unable to revert
the aggressive nature of this disease. Unsurprisingly, the lack of new
chemotherapeutic strategies is reﬂected in the small increase in pancre-
atic cancer survival over the past 30 years [5]. From this perspective, the
search for new drugs for pancreatic cancer therapy and the deﬁnition of
molecular mechanisms underlying their actions are crucial for improv-
ing the efﬁcacy of pancreatic cancer treatment. Calix[n]arenes have
emerged as promising anti-tumoral agents.
Calix[n]arenes are macrocyclic compounds of phenolic units
linked by methylene or sulfur groups at the 2,6-positions [6].
These compounds have been widely used for their diverse biological
properties. Calixarenes have shown potential as enzymatic inhibi-
tors [7–9], anticoagulants and antithrombotics [10], antivirals [11],
antimicrobials [12–14] and anticancer drugs [15–19]. Moreover,
calixarenes can be synthesized in large amounts, and can easily be
2857K.J. Pelizzaro-Rocha et al. / Biochimica et Biophysica Acta 1833 (2013) 2856–2865modiﬁed in order to improve molecular interactions with speciﬁc
target- or guest molecules [20].
In the present study, we reveal the mechanisms by which calix[6]
arene (CLX6) overcomes the aggressiveness of a human pancreatic can-
cer cell line (Panc-1). CLX6 dowregulated key protein kinases localized
in different cellular compartments resulting in cell cycle arrest,
downregulation of pro-survival mediators, endoplasmatic reticulum
stress and cell death by autophagy. These broad effects of CLX6
reinforced our hypothesis of its potential as a component of a pharma-
ceutical formulation for treating pancreatic cancer.
2. Materials and methods
2.1. Reagents
Calix[n]arenes (n = 4, 6 and 8) and derivatives were provided from
Dr Angelo de Fátima (Federal University of Minas Gerais, MG, Brazil).
Gemcitabine hydrochloride, 5-Fluorouracil, Propidium iodide (PI),
thiazolyl blue tetrazolium blue (MTT) and chloroquine were purchased
fromSigma-Aldrich (St. Louis,MO,USA). A Cell Proliferation ELISA, BrdU
(colorimetric) kit was obtained from Roche Applied Science
(Mannheim, Germany). Reagents for western blotting were purchased
from Bio-Rad (Hercules, CA, USA) and Sigma-Aldrich (St. Louis, MO,
USA). For western blotting, primary and HRP-conjugated secondary an-
tibodies were purchased from Cell Signaling Technology (Beverly, MA,
USA) and Sigma-Aldrich (St. Louis, MO, USA). For confocal microscopy,
rabbit polyclonal anti-LC3B was obtained from Cell Signaling Technolo-
gy (Beverly, MA) and Alexa-456 conjugated secondary antibody was
purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). Trans-
mission electronic microscopy reagents were purchased from Electron
Microscopy Sciences (Hatﬁeld, PA, USA) and Sigma-Aldrich (St. Louis,
MO, USA).
2.2. Cell culture
Pancreatic cancer cells (Panc-1) were purchased from the Rio de
Janeiro Cell Bank (Rio de Janeiro, RJ, Brazil). Panc-1 cells were cultured
in Dulbeco's modiﬁed Eagle's medium (DMEM) containing 100 U/mL
penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FSB),
at 37 °C in an humidiﬁed 5% CO2 atmosphere.
2.3. Treatment of Panc-1 with calix[n]arenes and derivatives
Panc-1 cells (1 × 105 cells/mL) were seeded in a 96-wells
microplate and after 24 h of culture cells were treated with different
concentrations (1, 5, 10, 25, 50 and 100 μM) of calix[n]arenes and
calix[n]arene derivatives and incubated for 24 h. Cell viability was ana-
lyzed by aMTT reduction assay as described below. Gemcitabine and 5-
Fluorouracil (in concentrations up to 2 mM) were used as controls. The
control group was treated with the equivalent amount of dimethyl
sulphoxide (DMSO, a maximum of 0.1% in the assay mixture was
used). Non-treated cell viability was set as 100% and IC50 values were
determined from three independent experiments.
2.4. Treatment of Panc-1 with CLX6 over time
Panc-1 cells (1 × 105 cells/mL) were seeded in a 96-wells
microplate and after 24 h the cells were treated with different concen-
trations (1, 5, 10, 25 and 50 μM) of CLX6. The cells were incubated for 3,
6, 12 and 24 h. Cell viability was analyzed by a MTT reduction assay as
described below. Non-treated cell viability at 0 h was set as 100%.
2.5. MTT reduction assay
The treatment medium was removed from the cells after each incu-
bation period. 100 μL of MTT solution (0.5 mg/mL in FBS free culturemedium) were added to each well. After incubating for 3 h at 37 °C,
the MTT solution was removed and the formed formazan crystals
were solubilized in 100 μL of ethanol. The plate was shaken for
10 min and the absorbance was measured at λ = 570 nm with a
microplate reader (Synergy HT, BioTek) [21]. Themeasured absorbance
at λ = 570 nmwas normalized to % of control. This value was calculat-
ed bymultiplying the absorbance of a treatedwell by 100 and dividing it
by the average absorbance of control wells.
2.6. BrdU incorporation assay
Panc-1 cells (1 × 105 cells/mL) were seeded in a black 96-wells
microplate and treated with different concentrations (0.1, 1, 5, 10, 25
and 50 μM) of CLX6 for 24 h. The BrdU incorporation assay was
performed in accordance with the manufacturer's instructions. In
brief, the cells were incubated with BrdU for 3 h. Next the Panc-1 cells
were ﬁxated and incubated with anti-BrdU for 90 min. Substrate was
added and incubated for 5 min and the chemiluminescence was mea-
sured with a microplate reader (Synergy HT, BioTek). The obtained
values were normalized to % of control. These values were calculated
multiplying the chemiluminescence measurements of treated wells by
100 and dividing them by the average chemiluminescence of control
wells, which were considered 100%.
2.7. Flow cytometry for cell-cycle analysis
After treatment with CLX6, cells were spun down, washed with PBS,
and resuspended in working solution (1 g/L sodium citrate, 0.5 mg/mL
ribonuclease A, 0.05 mg/mL propidium iodide (PI), 0.01% Triton X-100).
After incubating in the dark for 60 min at room temperature, the sam-
ples were analyzed using a Gallios ﬂow cytometer (Beckman Coulter,
USA).
2.8. Western blotting
After treatmentwith CLX6, Panc-1 cells were lysed in cell lysis buffer
(50 mM Tris–HCl (pH 7.4) containing 1% Tween 20, 0.25% sodium
deoxycholate, 150 mMNaCl, 1 mM EGTA, 1 mM o-vanadate, 1 mM so-
diumﬂuoride, 1 μg/mL aprotinin, 10 μg/mL leupeptin, and 1 mMPMSF)
for 2 h. After 10 min of centrifugation, the cleared lysates were
immunoprecipitated and resolved by reducing SDS-polyacrylamide gel
electrophoresis. The blots were incubated with indicated antibodies
and imaged by using chemiluminescence with an ImageQuant LAS
4000 (GE Healthcare Life Science).
2.9. Electron microscopy
Panc-1 cells were incubated in the presence or absence of CLX6 for
24 h and washed in 0.01 M phosphate-buffered saline (PBS), pelleted
and subsequently ﬁxed in 2.5% glutaraldehyde in 0.1 M cacodylate buff-
er for 48 h at 4 °C. The cells were postﬁxed in a solution containing 1%
osmium tetroxide and 0.8% potassium ferrocyanide in 0.1 M cacodylate
buffer, washed in the same buffer, dehydrated in different concentra-
tions of acetone, and embedded in Epon812 resin. Semithin sections
(65 nm)were stainedwith uranyl acetate and lead citrate. Next, images
were made with a transmission electron microscope (JEOL JM 1400).
2.10. Confocal microscopy
Panc-1 cells (4 × 104 cells/mL) were seeded 24 h before treatment
on glass coverslips (12 mm diameter) inside the 24-wells plates. Cells
were treated with 20 μM of CLX6 for 24 h. Next, cells were washed
with PBS, ﬁxed for 20 min with 4% p-formaldehyde (PFA) in PBS and
quenched with 0.1 M glycin in PBS for 20 min. Then, the cells were
permeabilized with 0.2% triton X-100 for 2 min, and blocked with 10%
serum solution for 5 min. Subsequently, cells were incubated with
Fig. 1.CLX6 reduces cell viability of pancreatic cancer cell (Panc-1). (A)Molecular structure of calix[n]arenes and derivatives. (B–C) Panc-1 cellswere treatedwith indicated compounds for
24 h. Cell viabilitywasmeasuredbyMTT assay and cell viability of non-treated cellswas considered as 100%. (D) Percentage of Panc-1 viable cells duringdifferent treatment times of CLX6.
After 0, 3, 6, 12 and 24 h of CLX6 treatment, the amount of viable Panc-1 cellswas quantiﬁed byMTT assay. Cell viability of treated and non-treated cells at 0 hwas considered as 100%. The
data was also plotted taking the control (non-treated cells) for each time point in consideration. Values are represented asmean ± SEM (n = 9). **p b 0.01, ***p b 0.001 versus control,
assessed with ANOVA followed by a Tukey test.
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at 37 °C in a humid chamber. Next, cells were washed once with PBS
and blocked for 1 min and incubated with a ﬂuorescently-labeled
secondary antibody (1:1000) diluted in blocking solution for 30 min
at 37 °C in a humid chamber. Cell nuclei were stained with DAPI. After
washing three times with PBS, coverslips were mounted on glass slides
using Dako mounting medium (Dako, Carpinteria, USA). Analyses were
performed at the National Institute of Science and Technology of
Photonics Applied to Cell Biology (INFABIC) at the State University of
Campinas. The samples were examined using a Zeiss LSM 780-NLOconfocal on an Axio Observer Z.1 microscope (Carl Zeiss AG, Germany)
equipped with a 60× oil immersion lens. The images were acquired
using the pinholes set to 1 airy unit for each channel in a sequential
manner and analyzed using ImageJ software (NIH).
2.11. Chloroquine treatment
To conﬁrm the role of autophagy in cell death induced by CLX6,
the autophagy inhibitor chloroquine (CLQ) was used. Panc-1 cells
(1 × 105 cells/mL) were grown in a 96-wells plate. Medium with
Fig. 2. CLX6 reduces cell proliferation due to cell-cycle arrest of pancreatic cancer cell (Panc-1). (A) Panc-1 cells were treatedwith CLX6 for 24 h. Cell proliferation wasmeasured by BrDU
assay and cell proliferation of non-treated cells was considered as 100%. (B) The amount of Panc-1 cells each cell cycle phase (G0/G1 phase, S phase and G2 + M) after treatment with
speciﬁed concentrations of CLX6 for 24 h was determined by propidium iodide staining followed by ﬂow cytometry. (C) Expression of CDK2, CDK4, Cyclin D1 and PIM1 kinase and
phosphorylation of retinoblastoma in Panc-1 cells, key proteins in cell-cycle control, was determined using western blotting. Equal loading was conﬁrmed by reprobing blots for
GAPDH. (D) Densitometric analysis. Results are presented as % of the control group (0 μM) (n = 3 independent experiments). Values are represented as mean ± SEM. *p b 0.05,
**p b 0.01, ***p b 0.001 versus control, assessed with ANOVA followed by a Tukey test.
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concentrations of CLX6. After 24 h, cell viability was assessed by a
MTT reduction assay as described in Section 2.5 in the methods.
2.12. Statistical analysis
All experiments were performed in triplicate and results are
expressed as mean ± standard error of the mean (SEM). Statistical
analyses were performed using ANOVA combined with a Post hoc
Tukey test. p b 0.05 was considered to be statistically signiﬁcant.
3. Results and discussion
3.1. CLX6 reduces the viability of pancreatic cancer cells
Six calixarenes (Fig. 1A)were evaluated for antitumor activity against
pancreatic cancer cells (Panc-1). Cell viability was assessed 24 h after
treatment by a MTT reduction assay. CLX6, which contains six phenolic
units, reduced Panc-1 cells viability in a dose-dependent manner
(Fig. 1B). The determined IC50 for Panc-1 cells treated with CLX6 for
24 h was 17.9 μM. In contrast, the CLX4, which contains four phenolic
units, was moderately effective, while CLX8 (containing eight phenolic
units) showed no viability reducing activity (Fig. 1B). Interestingly, the
introduction of a hydrophobic core (e.g. tert-butyl groups) in the upper
rim of calixarenes abolished the activity of these compounds irrespective
of calixarene cavity size (Fig. 1B). These results indicate that the cavity
size of calixarene is critical for its effects on Panc-1 cells.
Pancreatic cancer is considered an unsolved health problem due to
its aggressiveness. Although the current chemotherapeutic treatments
of pancreatic cancer can enhance the survival and quality of life ofpatients, they do not cure, even when treatment is initiated at early-
stage disease. Therefore, the identiﬁcation of novel potential anti-
pancreatic cancer agents and deﬁning their molecular mechanisms
are necessary [22]. To conﬁrm the potential of CLX6 against Panc-1
cells, the effects of gemcitabine and 5′ﬂuorouracil (current chemo-
therapeutic agents used in treatment of pancreatic cancer) were
also examined. Both compounds were evaluated in concentrations
up to 2 mM for 24 h, without resulting any observable decrease in
cellular viability (Fig. 1C). Also Erlotinib and Dasatinib (kinase
inhibitors), in concentrations up to 100 μM, did not affect Panc-1
cells viability (data not shown).
Since CLX6 proved to bemore effective than other calix[n]arenes, we
proceeded the molecular studies with this compound. We ﬁrstly inves-
tigated whether the reduced viable cell number was the result of a
reduction in cell cycle or due to an increase in cell death by measuring
the number of viable cells at different time points of treatment. We
considered the amount of MTT reduction of non-treated Panc-1 cells at
time 0 h as 100% viable. Treatment of Panc-1 cells for 24 h with 25
and 50 μM of CLX6 led to a reduction in cell viability of 46.6 ± 4.6%
and 67.3 ± 3.5%, respectively (Fig. 1D), whereas non-treated cells
exhibited 169.2 ± 2.4% viability. Therefore, we conclude that at these
concentrations CLX6 induces cell death in Panc-1 cells. However, 24 h
treatment of Panc-1 cells with 10 μM of CLX6 resulted in a viability of
92.5 ± 6.8%, a similar value was observed at 0 h (Fig. 1D). This data
suggests that 10 μM of CLX6 is not enough to induce cell death in
Panc-1 cells, but does appear to block cell proliferation. The discussed
data was also plotted taking the control (non-treated cells) for each
time point in consideration (Fig. 1D).
Our research grouphas a long-standing interest in anti-tumoral prop-
erty of natural or synthetic compounds and their derivatives [23–28]. In
Fig. 3. CLX6 downregulates receptor tyrosine kinases (AXL and Mer) and consequently inhibits PI3K/mTOR pathway of pancreatic cancer cell (Panc-1) treated with the compound for 24 h.
(A and C) Expression and/or activity state of Mer, AXL, HSP90, PI3K, AKT and mTOR were determined using western blotting. Equal loading was conﬁrmed by reprobing blots for GAPDH.
(B and D) Densitometric analysis. Results are presented as % of the control group (0 μM) (n = 3 independent experiments). Values are represented as mean ± SEM. *p b 0.05,
***p b 0.001 versus control, assessed with ANOVA followed by a Tukey test.
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therapeutic potential against pancreatic cancer as well as deﬁning their
molecular action mechanisms.
3.2. CLX6 induces cell-cycle arrest in pancreatic cancer cells
To test the hypothesis that CLX6 indeed blocks proliferation of
pancreatic cells, as indicated in Fig. 1C, we next examined its inﬂuence
on cell cycle progression by measuring BrDU and propidium iodide
incorporation. The BrDU assay revealed that 5 μM of CLX6 inhibited
cell proliferation by 73%, whereas 10 μM of CLX6 completely inhibited
cell proliferation (Fig. 2A). Furthermore, CLX6 induced cell-cycle arrest
in the G0/G1 phase (Fig. 2B) supported by the observation of an
increased number of cells in G0/G1 phase at all concentrations used,
while the number of cells in S andG2 + Mphase decreased. Importantly,
even at the lowest concentration of CLX6 (2.5 μM) 67.4 ± 1.3% of cells
were in G0/G1 phase compared to 29.1 ± 0.3% of non-treated cells.
Accordingly, the percentage of cells in S phase was reduced from
40.5 ± 1.5% in non-treated cells to 14.4 ± 4.4% in cells treated with
2.5 μM of CLX6. The same proﬁle was observed for treatments with 5
and 10 μM CLX6 (Fig. 2B).
Cancer progression has been suggested to include the loss of cell
cycle checkpoint controls that regulate passage through the cell cycle
[29]. There are a number of major checkpoints in the cell cycle that
are present at G1/S, S, G2/M andM-phase and each of these determines
whether cellswill proceed to thenext phase of the cycle [30–32]. TheG1
phase is controlled by many proteins, such as CDKs (cyclins kinase-
dependent) and cyclins. CDK2, 4 and 6 form a complex with cyclin D,
which phosphorylates retinoblastoma protein (RB), allowing the
passage through the point of restriction between the G1/S. Although
Cyclin D1 levels remained unaltered in cells treated with CLX6 (10
and 20 μM), a decrease in CDK2 and CDK4 expression was observed(Fig. 2C–D). Therefore, the lack of CDK4 is sufﬁcient to inhibit cell
cycle progression. Additionally, the downregulation of these cycle
progression modulators was followed by a reduction in the phosphory-
lation of retinoblastoma protein at Ser795 (Fig. 2C–D).
Moreover, a strong downregulation of PIM1 kinase, a key pro-
moter of cell proliferation, by CLX6 was observed (Fig. 2C–D). PIM
kinases have been shown to activate the phosphatases CDC25A and
CDC25C. These proteins promote cell cycle progression from G1 to
S and from G2 to M phases by activating CDKs [33,34]. Moreover,
PIM1 is known to repress the expression of p27 (an inhibitor of cell
cycle progression in G1-phase) as well as inactivate this protein by
phosphorylation [35]. Particularly in pancreatic cancer, PIM1 is a
promising therapeutic target, because of its important role in cancer
cell growth, invasion and radio resistance [36]. Furthermore, PIM1
was found to be upregulated in an in vitro model of pancreatic ductal
adenocarcinoma [37]. Interestingly, once expressed, PIM1 is consti-
tutively activated [38]; suggesting a direct link between PIM1
protein levels and its activity. Altogether these results allowed us
to conclude that CLX6 induces cell cycle arrest in the G0/G1 phase.
3.3. CLX6 modulates protein kinases responsible for controlling pancreatic
cancer cell survival and leads to endoplasmic reticulum stress
Since CLX6 caused a reduction in Panc-1 cell viability, we examined
the effects of this compound on key protein kinases involved in cell
survival. CLX6 caused a dramatic reduction in the amount of the AXL
and Mer receptor tyrosine kinases (RTK) in Panc-1 cells (Fig. 3A–B). In
accordance, downstream molecules of these receptors, PI3K and
mTOR, were negatively modulated as demonstrated by a decrease of
phosphorylation of Tyr458 and Ser2448 respectively, and consequently
the phospho-protein/protein ratios were lower compared to control
(Fig. 3C–D). Intriguingly, CLX6 was able to provoke different effects on
Fig. 4.CLX6 induces reticulum stress in pancreatic cancer cells. (A) Expression of IRE1 andBiP
and activation status of JNK2 were determined using western blotting. Equal loading was
conﬁrmed by reprobing blots for GAPDH. (B) Densitometric analysis. Results are presented
as % of the control group (0 μM) (n = 3 independent experiments). Values are represented
asmean ± SEM. **p b 0.01, ***p b 0.001 versus control, assessedwith ANOVA followed by a
Tukey test. Ultrastructural analysis of Panc-1 cells treated with (C) 10 μM and (D) 20 μM of
CLX6 for 24 h showed swollen and linear endoplasmatic reticulum (arrows).
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ylation at Ser473 increased while phosphorylation of Thr308 dropped
around 60% (Fig. 3C–D).
Receptor tyrosine kinases, including AXL and Mer, are involved in
cell proliferation, survival and tumor aggressiveness. AXL has been
reported to be overexpressed in many types of human malignancies,
including diffuse glioma, melanoma, osteosarcoma, and carcinomas of
lung, colon, prostate, breast, ovary, esophagus, stomach, and kidney
(reviewed by Verma et al. [39]). Recently, Song et al. [40] showed that
AXL and Gas6 (an AXL activator) are frequently overexpressed in
pancreatic ductal adenocarcinoma, and that AXL plays an important
role in anti-apoptosis and invasion mechanisms [40]. Activation of Mer
stimulates MAPK, AKT and FAK signaling pathways; indicating its role
in multiple oncogenic processes [41]. For instance, Mer is frequently
overexpressed and activated in non-small cell lung cancer cell lines
and inhibition of this kinase results in a complete blockade of cell
growth [41]. The mechanism by which CLX6 decreases the levels
of Mer and AXL needs to be investigated in more detail. However,
our hypothesis is that degradation of these receptors is stimulated
in the presence of CLX6. This hypothesis is based on the fact that we
also observed lower levels of heat shock protein 90 (HSP90) in
CLX6 treated cells compared to control cells (Fig. 3A–B). Recently,Krishnamoorthy et al. [42] reported that the blockade of HSP90 by 17-
allylamino-17-demethoxygeldanamycin induced AXL degradation via
the ubiquitin/proteasome pathway, and that the stability andmembrane
translocation of AXL are dependent on HSP90 [42].
Moreover, the observed decrease in receptor tyrosine kinase levels
could be responsible for the inhibition of the PI3K/mTOR pathway
triggered by CLX6. PI3K plays a critical role in the signaling network
that blocks programmed cell death by either apoptosis (through activa-
tion of AKT) or autophagy (through activation ofmTOR) and thus enables
cells to survive [43–47]. AKT signalingmodulates awide variety of cellular
processes throughphosphorylation ofmanyproteins, such asmTOR, BAD,
p21CIp, and GSK3 [48]. AKT can be activated by phosphorylation at two
residues: Thr308 and Ser473 [48]. It is important to highlight that the
maximal activity of AKT depends on the ratio of phosphorylation status
of both mentioned residues, rather than one site alone [48]. Yung et al.
[48] showed that Ser473 residue phosphorylation controls AKT substrate
speciﬁcity and therefore deﬁnes the cell fate, under reticulum stress
conditions. An important observation was the increased phosphorylation
of AKT at Ser473 and decreased phosphorylation at Thr308 after CLX6
treatment. This ﬁnding indicates that CLX6 induces endoplasmatic
reticulum (ER) stress, which can be responsible for modulating AKT.
Furthermore, ER stress has been reported to negatively modulate mTOR
and thereby enhance autophagy [49]. This ﬁnding is in agreement with
the strong inhibition of mTOR in cells treated with CLX6 and supports
the evidence for AKT modulation. Furthermore, mTOR inactivation has
also been related with cell cycle arrest in G0/G1 phase, an event also
observed in CLX6 treatment and discussed earlier, triggering autophagy
[27,45].
To determine whether ER stress is indeed involved in the effects
of CLX6 treatment, we evaluated ER stress markers and cellular
ultrastructures. Interestingly, BiP (an ER chaperone, also known as
GRP78) and IRE1-α, both ER stress markers, were upregulated by
CLX6 treatment (Fig. 4A–B). Ultrastructural analysis of Panc-1 cells
treated with CLX6 showed signiﬁcant changes in the structure of
the ER. CLX6 induced swelling and linearization of the ER, typical
signs of ER stress (Fig. 4C–D). Additionally, CLX6 treatment of
pancreatic cancer cells resulted in activation of JNK2. This kinase
has an important role as regulator of the endoplasmatic reticulum
structure and as stimulator of autophagic ﬂux [50]. Altogether,
these results suggest that CLX6 induces ER stress in Panc-1 cells.
3.4. Autophagy but not apoptosis is induced in pancreatic cancer cells after
CLX6 treatment
Since we observed that CLX6 treatment induced cycle arrest, ER
stress, JNK2 activation and inhibition of mTOR, we examined if CLX6
could induce autophagic cell death. Typically, autophagic processes
lead to speciﬁc ultrastructural changes. To evaluate this, we performed
electron microscopy analysis of Panc-1 cells treated with CLX6.
Pancreatic cancer cells treated with CLX6 presented double membrane
vacuolar structures with themorphological features of autophagosomes
(Fig. 5B–C). These structures were not observed in untreated cells
(Fig. 5A). In molecular context, LC3-II is considered one of the hallmarks
of autophagy [51]. CLX6-treated cells showed an increase in LC3-II levels
(Fig. 5D), concomitantly the occurrence of LC3-positive puncta was
observed (Fig. 5E–F). Autophagy is a dynamic process that can be mod-
ulated at several stages, both positive and negatively. The accumulation
of autophagosomes (measured by transmission electron microscopy
(TEM) image analysis, ﬂuorescent (LC3) dots, or LC3-II expression by
western blot) could reﬂect the induction of autophagy, reduction in
autophagosome turnover [52], or inability in autophagosome formation
[53]. Therefore, to avoidmisleading results we tested the effects of CLX6
on Panc-1 cells in the presence of chloroquine (an autophagy inhibitor).
Chloroquine elevates (thus neutralizes) the lysosomal/vacuolar pH;
blocking autophagosome–lysosome fusion. Chloroquine abrogated the
toxic effect of CLX6-treated cells (Fig. 6). Taken together, our data
Fig. 5. CLX6 induces autophagy in pancreatic cancer cells (Panc-1). (A) Ultrastructure of non-treated cells. Ultrastructural analysis of Panc-1 cells treatedwith (B) 10 μMand (C) 20 μMof CLX6
for 24 h. (D) LC3B I/II expression was determined using western blotting. Equal loading was conﬁrmed by reprobing blots for GAPDH. (E) Densitometric analysis. Results are presented as % of
the control group (0 μM) (n = 3 independent experiments). Values are represented as mean ± SEM. ***p b 0.001 versus control, assessed with ANOVA followed by a Tukey test. (F–G)
Intracellular localization of LC3B in Panc-1 cells. (G) Cells were exposed to CLX6 (20 μM) for 24 h to determine the presence and location of autophagosome. (F) Control group.
Fig. 6. Chloroquine abrogates the toxic effect of CLX6 in Panc-1 treated cells. Panc-1 cells
were treated with CLX6 in the presence or absence of chloroquine (50 μM) for 24 h. Cell
viability wasmeasured byMTT assay and cell viability of non-treated cells was considered
as 100%. Values are represented as mean ± SEM (n = 9). ***p b 0.001 versus control as
assessed by ANOVA followed by a Tukey test.
2862 K.J. Pelizzaro-Rocha et al. / Biochimica et Biophysica Acta 1833 (2013) 2856–2865indicates that autophagy plays an important role in cell death caused in
Panc-1 cells by CLX6 treatment. Furthermore, these results uncovered
functional links between ER stress and autophagic cell death induced
by CLX6.
The role of autophagy in cancer cell survival is controversial; it can
either help cells to survive during stress or can mediate cell death. In
some cancer cells, especially when essential apoptotic modulators such
as BAX and Bak or caspases are lost or dysfunctional, autophagy may
lead to cell death [54,55]. Some studies have demonstrated that pancre-
atic cancers present high levels of procaspase-3, Bcl-XL and FAP-1,
proteins that lead to caspase-dependent apoptosis resistance [56–58].
Accordingly, apoptosis markers were unaffected by CLX6: both treated
and non-treated cells displayed similar levels of pro-apoptotic BAX and
anti-apoptotic Bcl2 proteins, and no cleaved Caspase-3 was observed
(Fig. 7). Taken together, these data clearly indicate that apoptosis
has little or no contribution in the cell death caused by CLX6 in
Panc-1 cells, but show that autophagy is an important process in
driving Panc-1 cell death.
Fig. 7. CLX6 does not induce apoptosis through the canonical pathway. Expression of BCL2, BAX, and pro-Caspase-3 was determined using western blotting. Equal loading was conﬁrmed by
reprobing blots for GAPDH. (B) Densitometric analysis. Results are presented as % of the control group (0 μM) (n = 3 independent experiments). Values are represented as mean ± SEM.
Statistical signiﬁcance compared to control was assessed by ANOVA followed by a Tukey test.
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Nowadays, it is well recognized that deﬁning the molecular action
of potential drugs is crucial for developing more speciﬁc and potent
therapies, as well as for predicting possible side effects. The results
presented in this study, show for the ﬁrst time that CLX6 is highly
effective in inducing cell death in human pancreatic ductal adeno-
carcinoma cells. So far, no study has described the details of the
molecular action of this compound. We show that CLX6 abolished
Mer and AXL receptor tyrosine kinase dependent signal trans-
duction, both of which are usually overexpressed in this type of
tumor, and that CLX6 inhibited the PI3K/mTOR pathway. Apart
from this, cell cycle arrest and ER stress induced by this compound
contribute to autophagic cell death. Overall, our ﬁndings provide
strong evidence of the large effects of CLX6 in reducing Panc-1 cell
aggressiveness, since key pro-survival players were downmodulated
by this compound. This study highlights the importance of the
thorough description of the molecular mechanism responsible
for the biological effects of new compounds and opens a new possi-
bility for improving the efﬁcacy of pancreatic cancer therapy.
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